Latest News and Press Releases

Phase 1 umbrella trial for TSC-100 and TSC-101 in hematologic malignancies on track to enroll patients into each of the three study arms and provide a clinical update including safety and biomarker...

WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...

Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on target and HLA expression INDs for...

Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development...

WALTHAM, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...

WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...

TCRs for an HLA-A*02:01 epitope of PRAME now in IND-enabling studies Multiplexing TCRs for MAGE-A1 and PRAME demonstrates synergistic cytotoxicity in vitro and in mouse xenograft models Company...

Four sites for hematologic malignancies program open and enrolling patients Completed pre-IND meeting with the FDA for solid tumor program; virtual investor event Monday, November 14, at 5:00 PM ET...